CAR T-cell therapy is a cancer treatment that reprograms your own immune cells to find and destroy cancer. Unlike chemotherapy, which kills fast-growing cells indiscriminately, this approach turns your T cells (the immune system’s natural hunters) into precision weapons by giving them a new receptor designed to lock onto cancer cells. Seven CAR T products are currently approved by the FDA, all for blood cancers, and the treatment can produce lasting remissions even in patients who’ve run out of other options.
How CAR T Cells Work
Your immune system already uses T cells to patrol for threats, but cancer cells are skilled at hiding from them. CAR T-cell therapy solves this by adding a synthetic receptor, called a chimeric antigen receptor, to the surface of your T cells. This receptor has four parts: an outer domain that recognizes a specific protein on cancer cells, a hinge and a transmembrane section that anchor the receptor in place, and an inner signaling domain that flips the T cell into attack mode when contact is made.
Once infused back into your body, these engineered cells circulate through your bloodstream, latch onto cancer cells displaying the target protein, and kill them. The CAR T cells also multiply after activation, building a small army that continues hunting. In some patients, these cells persist in the body for years, acting as a living surveillance system against relapse.
What the Treatment Process Looks Like
The entire process takes roughly three months from the initial eligibility assessment through your post-infusion monitoring period. Here’s how it unfolds.
First, your medical team runs tests and scans over about five to seven days to confirm you’re a candidate. Insurance approval adds another 10 to 14 days on average, sometimes up to four weeks. Once cleared, you undergo a blood-draw procedure called apheresis, where a machine separates T cells from your blood and returns the rest. You’ll need a caregiver with you during this step.
Your T cells are then shipped to a manufacturing facility, where they’re genetically modified to carry the new receptor and grown into large numbers. This manufacturing phase, sometimes called “vein-to-vein time,” currently averages three to six weeks. During this wait, some patients receive bridging chemotherapy to keep the cancer in check, though not everyone needs it.
Just before your engineered cells are ready, you’ll receive a short course of lymphodepletion chemotherapy. This suppresses your existing immune system so the new CAR T cells have room to expand and work effectively. Every patient getting CAR T therapy goes through this step.
The infusion itself is surprisingly quick, typically 15 minutes to an hour depending on the volume of cells. It looks similar to a blood transfusion. After that, you enter a 30-day close monitoring period. The first two weeks may be spent in the hospital or at daily outpatient visits nearby, with the remaining time as a less frequent outpatient.
Which Cancers It Treats
All seven FDA-approved CAR T products target blood cancers. The approved indications include certain types of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukemia (primarily in young patients), and multiple myeloma. These therapies are generally reserved for patients whose cancer has returned after other treatments or hasn’t responded to them, meaning CAR T is not typically a first-line option.
The approved products target one of two proteins found on the surface of cancerous blood cells. Most target a protein called CD19, which sits on the surface of B cells in lymphoma and leukemia. The multiple myeloma products target a different protein called BCMA. The choice of product depends on your specific cancer type and which protein your cancer cells carry.
Long-Term Survival Outcomes
For a therapy originally viewed as a last resort, the long-term data are striking. A study published in Blood Advances tracked patients with B-cell non-Hodgkin lymphoma who received CAR T therapy targeting CD19 and followed them for a full decade. The 10-year overall survival rate was 58.1% for all patients, and among those with large B-cell lymphoma specifically, it was 50.7%.
The results were even more dramatic for patients who achieved a complete response, meaning no detectable cancer after treatment. Their 10-year overall survival reached 81.9%, and their five-year event-free survival (no relapse, no need for new treatment) was 87%. These numbers suggest that for patients who respond fully, CAR T therapy can function as a one-time, potentially curative treatment.
Not everyone responds this well. About half of patients with large B-cell lymphoma remained event-free at five years, which means the other half experienced relapse or progression. Predicting who will achieve a complete response remains one of the central challenges.
Side Effects and Risks
CAR T-cell therapy causes side effects that are distinct from traditional chemotherapy. The most common is cytokine release syndrome (CRS), which happens when the newly activated CAR T cells flood the body with inflammatory signals. Mild CRS feels like a bad flu: high fever, muscle aches, fatigue. Severe cases can cause dangerously low blood pressure, difficulty breathing, and organ stress. CRS typically appears within the first week after infusion and is the main reason for close hospital monitoring during that period.
The second major risk is neurotoxicity, sometimes called ICANS. Symptoms range from mild confusion, difficulty finding words, and tremors to more serious events like seizures. These neurological effects usually appear after CRS begins and resolve on their own in most patients, though they can be frightening. Medical teams at CAR T treatment centers are trained to recognize and manage both CRS and neurotoxicity early.
Because lymphodepletion chemotherapy wipes out much of your immune system before infusion, you’ll have a period of increased vulnerability to infections. Your blood cell counts, particularly infection-fighting white blood cells, may stay low for weeks or months. Some patients also experience long-term low levels of certain antibodies and need periodic infusions to compensate.
Why It Doesn’t Yet Work for Solid Tumors
Solid tumors like pancreatic, lung, or brain cancers present a fundamentally different challenge. In blood cancers, CAR T cells circulate freely and encounter cancer cells in the bloodstream and lymph nodes. Solid tumors are walled-off structures, and getting CAR T cells inside them is the first major hurdle. Tumors lack the chemical signals that would normally guide immune cells to the right location, their blood vessels are abnormal, and a dense layer of supportive tissue acts as a physical barrier.
Even when CAR T cells do infiltrate a solid tumor, the environment inside actively suppresses them. Tumors create conditions that exhaust T cells and strip away their ability to kill. On top of that, solid tumors are genetically diverse. Cancer cells within the same tumor may carry different surface proteins, so even if CAR T cells destroy cells displaying the target, other cells without that target survive and grow back. This phenomenon, called antigen escape, is one of the biggest obstacles in the field.
Cost of Treatment
CAR T-cell therapy is one of the most expensive treatments in medicine. The 2025 wholesale list prices for three of the major products illustrate the scale: Kymriah costs $593,533, Breyanzi costs $531,350, and Yescarta costs $503,580. These figures cover only the drug itself and don’t include hospitalization, the lymphodepletion chemotherapy, monitoring, or management of side effects, all of which add substantially to the total bill.
Most patients receive CAR T therapy through insurance, and hospitals negotiate rates that vary widely. Private insurers paid hospitals an average of 254% of Medicare prices for hospital care in 2022, which means the actual amount billed depends heavily on your coverage. Newer manufacturing approaches, including point-of-care production that can cut the vein-to-vein timeline to 7 to 14 days, could eventually reduce costs by eliminating the need to ship cells to a centralized facility and shortening the wait that sometimes requires expensive bridging chemotherapy.